Inhibition of USP10 induces degradation of oncogenic FLT3

Ellen L. Weisberg, Nathan J. Schauer, Jing Yang, Ilaria Lamberto, Laura Doherty, Shruti Bhatt, Atsushi Nonami, Chengcheng Meng, Anthony Letai, Renee Wright, Hong Tiv, Prafulla C. Gokhale, Maria Stella Ritorto, Virginia De Cesare, Matthias Trost, Alexandra Christodoulou, Amanda Christie, David M. Weinstock, Sophia Adamia, Richard StoneDharminder Chauhan, Kenneth C. Anderson, Hyuk Soo Seo, Sirano Dhe-Paganon, Martin Sattler, Nathanael S. Gray, James D. Griffin, Sara J. Buhrlage

研究成果: ジャーナルへの寄稿記事

20 引用 (Scopus)

抄録

Oncogenic forms of the kinase FLT3 are important therapeutic targets in acute myeloid leukemia (AML); however, clinical responses to small-molecule kinase inhibitors are short-lived as a result of the rapid emergence of resistance due to point mutations or compensatory increases in FLT3 expression. We sought to develop a complementary pharmacological approach whereby proteasome-mediated FLT3 degradation could be promoted by inhibitors of the deubiquitinating enzymes (DUBs) responsible for cleaving ubiquitin from FLT3. Because the relevant DUBs for FLT3 are not known, we assembled a focused library of most reported small-molecule DUB inhibitors and carried out a cellular phenotypic screen to identify compounds that could induce the degradation of oncogenic FLT3. Subsequent target deconvolution efforts allowed us to identify USP10 as the critical DUB required to stabilize FLT3. Targeting of USP10 showed efficacy in preclinical models of mutant-FLT3 AML, including cell lines, primary patient specimens and mouse models of oncogenic-FLT3-driven leukemia.

元の言語英語
ページ(範囲)1207-1215
ページ数9
ジャーナルNature Chemical Biology
13
発行部数12
DOI
出版物ステータス出版済み - 12 1 2017

Fingerprint

Acute Myeloid Leukemia
Phosphotransferases
Proteasome Endopeptidase Complex
Ubiquitin
Point Mutation
Libraries
Leukemia
Pharmacology
Cell Line
Therapeutics
Deubiquitinating Enzymes

All Science Journal Classification (ASJC) codes

  • Molecular Biology
  • Cell Biology

これを引用

Weisberg, E. L., Schauer, N. J., Yang, J., Lamberto, I., Doherty, L., Bhatt, S., ... Buhrlage, S. J. (2017). Inhibition of USP10 induces degradation of oncogenic FLT3. Nature Chemical Biology, 13(12), 1207-1215. https://doi.org/10.1038/nchembio.2486

Inhibition of USP10 induces degradation of oncogenic FLT3. / Weisberg, Ellen L.; Schauer, Nathan J.; Yang, Jing; Lamberto, Ilaria; Doherty, Laura; Bhatt, Shruti; Nonami, Atsushi; Meng, Chengcheng; Letai, Anthony; Wright, Renee; Tiv, Hong; Gokhale, Prafulla C.; Ritorto, Maria Stella; De Cesare, Virginia; Trost, Matthias; Christodoulou, Alexandra; Christie, Amanda; Weinstock, David M.; Adamia, Sophia; Stone, Richard; Chauhan, Dharminder; Anderson, Kenneth C.; Seo, Hyuk Soo; Dhe-Paganon, Sirano; Sattler, Martin; Gray, Nathanael S.; Griffin, James D.; Buhrlage, Sara J.

:: Nature Chemical Biology, 巻 13, 番号 12, 01.12.2017, p. 1207-1215.

研究成果: ジャーナルへの寄稿記事

Weisberg, EL, Schauer, NJ, Yang, J, Lamberto, I, Doherty, L, Bhatt, S, Nonami, A, Meng, C, Letai, A, Wright, R, Tiv, H, Gokhale, PC, Ritorto, MS, De Cesare, V, Trost, M, Christodoulou, A, Christie, A, Weinstock, DM, Adamia, S, Stone, R, Chauhan, D, Anderson, KC, Seo, HS, Dhe-Paganon, S, Sattler, M, Gray, NS, Griffin, JD & Buhrlage, SJ 2017, 'Inhibition of USP10 induces degradation of oncogenic FLT3', Nature Chemical Biology, 巻. 13, 番号 12, pp. 1207-1215. https://doi.org/10.1038/nchembio.2486
Weisberg EL, Schauer NJ, Yang J, Lamberto I, Doherty L, Bhatt S その他. Inhibition of USP10 induces degradation of oncogenic FLT3. Nature Chemical Biology. 2017 12 1;13(12):1207-1215. https://doi.org/10.1038/nchembio.2486
Weisberg, Ellen L. ; Schauer, Nathan J. ; Yang, Jing ; Lamberto, Ilaria ; Doherty, Laura ; Bhatt, Shruti ; Nonami, Atsushi ; Meng, Chengcheng ; Letai, Anthony ; Wright, Renee ; Tiv, Hong ; Gokhale, Prafulla C. ; Ritorto, Maria Stella ; De Cesare, Virginia ; Trost, Matthias ; Christodoulou, Alexandra ; Christie, Amanda ; Weinstock, David M. ; Adamia, Sophia ; Stone, Richard ; Chauhan, Dharminder ; Anderson, Kenneth C. ; Seo, Hyuk Soo ; Dhe-Paganon, Sirano ; Sattler, Martin ; Gray, Nathanael S. ; Griffin, James D. ; Buhrlage, Sara J. / Inhibition of USP10 induces degradation of oncogenic FLT3. :: Nature Chemical Biology. 2017 ; 巻 13, 番号 12. pp. 1207-1215.
@article{490649a3165845eda6c5ca8ee71bdfa8,
title = "Inhibition of USP10 induces degradation of oncogenic FLT3",
abstract = "Oncogenic forms of the kinase FLT3 are important therapeutic targets in acute myeloid leukemia (AML); however, clinical responses to small-molecule kinase inhibitors are short-lived as a result of the rapid emergence of resistance due to point mutations or compensatory increases in FLT3 expression. We sought to develop a complementary pharmacological approach whereby proteasome-mediated FLT3 degradation could be promoted by inhibitors of the deubiquitinating enzymes (DUBs) responsible for cleaving ubiquitin from FLT3. Because the relevant DUBs for FLT3 are not known, we assembled a focused library of most reported small-molecule DUB inhibitors and carried out a cellular phenotypic screen to identify compounds that could induce the degradation of oncogenic FLT3. Subsequent target deconvolution efforts allowed us to identify USP10 as the critical DUB required to stabilize FLT3. Targeting of USP10 showed efficacy in preclinical models of mutant-FLT3 AML, including cell lines, primary patient specimens and mouse models of oncogenic-FLT3-driven leukemia.",
author = "Weisberg, {Ellen L.} and Schauer, {Nathan J.} and Jing Yang and Ilaria Lamberto and Laura Doherty and Shruti Bhatt and Atsushi Nonami and Chengcheng Meng and Anthony Letai and Renee Wright and Hong Tiv and Gokhale, {Prafulla C.} and Ritorto, {Maria Stella} and {De Cesare}, Virginia and Matthias Trost and Alexandra Christodoulou and Amanda Christie and Weinstock, {David M.} and Sophia Adamia and Richard Stone and Dharminder Chauhan and Anderson, {Kenneth C.} and Seo, {Hyuk Soo} and Sirano Dhe-Paganon and Martin Sattler and Gray, {Nathanael S.} and Griffin, {James D.} and Buhrlage, {Sara J.}",
year = "2017",
month = "12",
day = "1",
doi = "10.1038/nchembio.2486",
language = "English",
volume = "13",
pages = "1207--1215",
journal = "Nature Chemical Biology",
issn = "1552-4450",
publisher = "Nature Publishing Group",
number = "12",

}

TY - JOUR

T1 - Inhibition of USP10 induces degradation of oncogenic FLT3

AU - Weisberg, Ellen L.

AU - Schauer, Nathan J.

AU - Yang, Jing

AU - Lamberto, Ilaria

AU - Doherty, Laura

AU - Bhatt, Shruti

AU - Nonami, Atsushi

AU - Meng, Chengcheng

AU - Letai, Anthony

AU - Wright, Renee

AU - Tiv, Hong

AU - Gokhale, Prafulla C.

AU - Ritorto, Maria Stella

AU - De Cesare, Virginia

AU - Trost, Matthias

AU - Christodoulou, Alexandra

AU - Christie, Amanda

AU - Weinstock, David M.

AU - Adamia, Sophia

AU - Stone, Richard

AU - Chauhan, Dharminder

AU - Anderson, Kenneth C.

AU - Seo, Hyuk Soo

AU - Dhe-Paganon, Sirano

AU - Sattler, Martin

AU - Gray, Nathanael S.

AU - Griffin, James D.

AU - Buhrlage, Sara J.

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Oncogenic forms of the kinase FLT3 are important therapeutic targets in acute myeloid leukemia (AML); however, clinical responses to small-molecule kinase inhibitors are short-lived as a result of the rapid emergence of resistance due to point mutations or compensatory increases in FLT3 expression. We sought to develop a complementary pharmacological approach whereby proteasome-mediated FLT3 degradation could be promoted by inhibitors of the deubiquitinating enzymes (DUBs) responsible for cleaving ubiquitin from FLT3. Because the relevant DUBs for FLT3 are not known, we assembled a focused library of most reported small-molecule DUB inhibitors and carried out a cellular phenotypic screen to identify compounds that could induce the degradation of oncogenic FLT3. Subsequent target deconvolution efforts allowed us to identify USP10 as the critical DUB required to stabilize FLT3. Targeting of USP10 showed efficacy in preclinical models of mutant-FLT3 AML, including cell lines, primary patient specimens and mouse models of oncogenic-FLT3-driven leukemia.

AB - Oncogenic forms of the kinase FLT3 are important therapeutic targets in acute myeloid leukemia (AML); however, clinical responses to small-molecule kinase inhibitors are short-lived as a result of the rapid emergence of resistance due to point mutations or compensatory increases in FLT3 expression. We sought to develop a complementary pharmacological approach whereby proteasome-mediated FLT3 degradation could be promoted by inhibitors of the deubiquitinating enzymes (DUBs) responsible for cleaving ubiquitin from FLT3. Because the relevant DUBs for FLT3 are not known, we assembled a focused library of most reported small-molecule DUB inhibitors and carried out a cellular phenotypic screen to identify compounds that could induce the degradation of oncogenic FLT3. Subsequent target deconvolution efforts allowed us to identify USP10 as the critical DUB required to stabilize FLT3. Targeting of USP10 showed efficacy in preclinical models of mutant-FLT3 AML, including cell lines, primary patient specimens and mouse models of oncogenic-FLT3-driven leukemia.

UR - http://www.scopus.com/inward/record.url?scp=85034845782&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85034845782&partnerID=8YFLogxK

U2 - 10.1038/nchembio.2486

DO - 10.1038/nchembio.2486

M3 - Article

C2 - 28967922

AN - SCOPUS:85034845782

VL - 13

SP - 1207

EP - 1215

JO - Nature Chemical Biology

JF - Nature Chemical Biology

SN - 1552-4450

IS - 12

ER -